LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

21.45 -0.23

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

21.45

Max

21.45

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.6M -21M
Verkäufe	14M 54M
Gewinnspanne	-39.611
Angestellte	178
EBITDA	-3.8M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-3.62% downside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1B 2.2B
Vorheriger Eröffnungskurs	21.68
Vorheriger Schlusskurs	21.45

Nachrichtenstimmung

By Acuity

50%

155 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.26 / 7.47 Unterstützung & Widerstand

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Mai 2026, 22:47 UTC

Heiße Aktien

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15. Mai 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15. Mai 2026, 22:00 UTC

Wichtige Markttreiber

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15. Mai 2026, 18:09 UTC

Wichtige Markttreiber

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15. Mai 2026, 16:02 UTC

Ergebnisse

Wichtige Markttreiber

Forward Industries Shares Fall on New Debt as Solana Value Drops

15. Mai 2026, 14:55 UTC

Wichtige Markttreiber

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15. Mai 2026, 14:43 UTC

Wichtige Markttreiber

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15. Mai 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. Mai 2026, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15. Mai 2026, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. Mai 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15. Mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15. Mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. Mai 2026, 20:19 UTC

Heiße Aktien

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15. Mai 2026, 19:41 UTC

Akquisitionen, Fusionen, Übernahmen

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15. Mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15. Mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15. Mai 2026, 18:35 UTC

Ergebnisse

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15. Mai 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15. Mai 2026, 16:50 UTC

Akquisitionen, Fusionen, Übernahmen

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15. Mai 2026, 16:24 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15. Mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15. Mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. Mai 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15. Mai 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Mai 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15. Mai 2026, 15:20 UTC

Ergebnisse

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15. Mai 2026, 14:33 UTC

Market Talk

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

-3.62% Nachteil

12-Monats-Prognose

Durchschnitt 20.75 USD -3.62%

Hoch 21.5 USD

Tief 17 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

155 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.